Comments
Generic drug maker Hetero has launched biosimilar drug Bevacizumab for the treatment of metastatic colorectal cancer (mCRC) under the brand Cizumab. The product was approved by the Drug Controller General of India and was recommended as a first line treatment for mCRC, the Hyderabad-based company said in a release issued here on Monday. The product will be manufactured in Hetero’s biologics facility here.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.